Vol 52, No 3 (2021)
Original research article
Published online: 2021-06-28

open access

Page views 446
Article views/downloads 339
Get Citation

Connect on Social Media

Connect on Social Media

Blood type does not modify prognosis in patients with COVID-19: experience in a COVID-19 hospital in Mexico

Christian Ramos-Peñafiel12, Elizabeth Mader-Maldonado1, Carlos Martínez-Murillo2, Irma Olarte-Carrillo2, Carolina Balderas-Delgado1, Álvaro Cabrera-García1, Ubaldo Valencia-Rocha1, Emmanuel Bermeo-Maldonado1, Adrián Santoyo-Sánchez2, Adolfo Martínez-Tovar2
Acta Haematol Pol 2021;52(3):190-194.

Abstract

Introduction: According to reports from China and Europe, there are various clinical and laboratory risk factors that associate with both death and the use of a ventilator in coronavirus disease 2019 (COVID-19). In Wuhan, blood type A was related to these complications, but this factor is unknown for Latin America. Objective was to describe the association of blood type with complications related to COVID-19 infection. Material and methods: A retrospective comparative study from the clinical files of patients cared for in the emergency department between April and May 2020. Results: Data was analyzed from 120 patients hospitalized with COVID-19 infection. There were no differences in age and gender by blood type. Type O was the most frequent (80.8%) followed by type A (11.7%) and type B (7.5%). In univariate analysis, there was no impact of blood type on survival, individually (groups A, B, O) (log rank 0.154). In multivariate analysis, only age influenced prognosis (p =0.004). Above the risk, type O showed no impact on mortality (OR 1.0119, 95% CI: 0.3898–2.6272, p =0.980) or ventilator use (1.5616, 95% CI: 0.4834–5.0453, p =0.456), likewise for types A and B (OR 0.9882, 95% CI, 0.3806–2.5657). Conclusion: Blood type does not impact prognosis in Mexican patients with COVID-19.

Article available in PDF format

View PDF Download PDF file

References

  1. The Johns Hopkins Coronavirus Resource Center 2020. https://coronavirus.jhu.edu/ (November 1, 2020).
  2. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229): 1054–1062.
  3. Parohan M, Yaghoubi S, Seraji A, et al. Risk factors for mortality in patients with coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. Aging Male. 2020; 23(5): 1416–1424.
  4. Huang I, Pranata R. Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis. J Intensive Care. 2020; 8: 36.
  5. Xia Z. Eosinopenia as an early diagnostic marker of COVID-19 at the time of the epidemic. EClinicalMedicine. 2020; 23: 100398.
  6. Zhao Q, Meng M, Kumar R, et al. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a systemic review and meta-analysis. Int J Infect Dis. 2020; 96: 131–135.
  7. Zaki N, Alashwal H, Ibrahim S. Association of hypertension, diabetes, stroke, cancer, kidney disease, and high-cholesterol with COVID-19 disease severity and fatality: A systematic review. Diabetes Metab Syndr. 2020; 14(5): 1133–1142.
  8. Bikdeli B, Madhavan MV, Jimenez D, et al. Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol. 2020; 75(23): 2950–2973.
  9. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020; 95(7): 834–847.
  10. Ciccullo A, Borghetti A, Zileri Dal Verme L, et al. GEMELLI AGAINST COVID Group. Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line. Int J Antimicrob Agents. 2020; 56(2): 106017.
  11. Miyasaka M. Is BCG vaccination causally related to reduced COVID-19 mortality? EMBO Mol Med. 2020; 12(6): e12661.
  12. Shah M, Sachdeva M, Dodiuk-Gad RP. COVID-19 and racial disparities. J Am Acad Dermatol. 2020; 83(1): e35.
  13. Li J, Wang X, Chen J, et al. Association between ABO blood groups and risk of SARS-CoV-2 pneumonia. Br J Haematol. 2020; 190(1): 24–27.
  14. Hosoi E. Biological and clinical aspects of ABO blood group system. J Med Invest. 2008; 55(3-4): 174–182.
  15. Lu L, Zhong W, Bian Z, et al. A comparison of mortality-related risk factors of COVID-19, SARS, and MERS: a systematic review and meta-analysis. J Infect. 2020; 81(4): e18–e25.
  16. Zhang Z, Yao W, Wang Y, et al. Wuhan and Hubei COVID-19 mortality analysis reveals the critical role of timely supply of medical resources. J Infect. 2020; 81(1): 147–178.
  17. Franchini M, Liumbruno GM, Lippi G. The prognostic value of ABO blood group in cancer patients. Blood Transfus. 2016; 14(5): 434–440.
  18. Xu YQ, Jiang TW, Cui YH, et al. Prognostic value of ABO blood group in patients with gastric cancer. J Surg Res. 2016; 201(1): 188–195.
  19. Chakrani Z, Robinson K, Taye B. Association between ABO blood groups and Helicobacter pylori infection: a meta-analysis. Sci Rep. 2018; 8(1): 17604.
  20. Liu J, Zhang S, Wang Q, et al. Frequencies and ethnic distribution of ABO and RhD blood groups in China: a population-based cross-sectional study. BMJ Open. 2017; 7(12): e018476.
  21. Canizalez-Román A, Campos-Romero A, Castro-Sánchez JA, et al. Blood groups distribution and gene diversity of the ABO and Rh (D) in the Mexican population. Biomed Res Int. 2018; 2018: 1925619.
  22. Zietz M, Zucker J, Tatonetti NP. Testing the association between blood type and COVID-19 infection, intubation, and death. medRxiv. 2020.